Gastric Cancer

, Volume 7, Issue 2, pp 104–109

Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer

  • Taira Kinoshita
  • Atsushi Nashimoto
  • Yoshitaka Yamamura
  • Takeshi Okamura
  • Mitsuru Sasako
  • Junichi Sakamoto
  • Hiroshi Kojima
  • Masahiro Hiratsuka
  • Kuniyoshi Arai
  • Motonori Sairenji
  • Norimasa Fukushima
  • Hironobu Kimura
  • Toshifusa Nakajima
Original article

DOI: 10.1007/s10120-004-0278-3

Cite this article as:
Kinoshita, T., Nashimoto, A., Yamamura, Y. et al. Gastric Cancer (2004) 7: 104. doi:10.1007/s10120-004-0278-3

Abstract

Background

We conducted a feasibility study using S-1, a novel oral derivative of 5-fluorouracil, as postoperative adjuvant chemotherapy for curatively resected gastric cancer patients.

Methods

Adjuvant chemotherapy consisted of eight courses (4-week administration and 2-week withdrawal) of S-1, at 80–120 mg/body per day. Forty-one patients from 11 institutions were enrolled in this pilot study, from November 1999 to October 2000.

Results

Thirty-five patients were eligible. In 7 patients, S-1 administration was discontinued due to recurrence. Among the 28 patients without recurrence, the planned eight courses of S-1 were administered to 17 patients (60.7%). In 4 patients, S-1 administration was discontinued due to subjective symptoms, such as anorexia, in the first course. Adverse reactions such as neutropenia, leukopenia, elevated total bilirubin, anorexia, general fatigue, diarrhea, nausea, and stomatitis were seen in more than half of the patients. Although grade 3 neutropenia (29.3%), leukopenia (9.8%), and diarrhea (9.8%) were observed, no grade 4 adverse effects appeared. Compared with the treatment of unresectable or recurrent gastric cancer with S-1, the incidence of adverse reactions in the adjuvant setting was slightly higher, probably due to the influence of gastrectomy.

Conclusion

Except for the early development of anorexia, most likely due to adverse effects of surgery, postoperative administration of S-1 for 1 year seems feasible as adjuvant chemotherapy for gastric cancer.

Key words

Gastric cancer S-1 Adjuvant chemotherapy Feasibility study 

Copyright information

© Springer-Verlag Tokyo 2004

Authors and Affiliations

  • Taira Kinoshita
    • 1
  • Atsushi Nashimoto
    • 2
  • Yoshitaka Yamamura
    • 3
  • Takeshi Okamura
    • 4
  • Mitsuru Sasako
    • 5
  • Junichi Sakamoto
    • 6
  • Hiroshi Kojima
    • 6
  • Masahiro Hiratsuka
    • 7
  • Kuniyoshi Arai
    • 8
  • Motonori Sairenji
    • 9
  • Norimasa Fukushima
    • 10
  • Hironobu Kimura
    • 11
  • Toshifusa Nakajima
    • 12
  1. 1.Department of Surgical OncologyNational Cancer Center Hospital EastChibaJapan
  2. 2.Niigata Cancer Center HospitalNiigataJapan
  3. 3.Aichi Cancer Center HospitalNagoyaJapan
  4. 4.National Kyushu Cancer CenterFukuokaJapan
  5. 5.National Cancer Center HospitalTokyoJapan
  6. 6.Aichi Prefectural HospitalOkazakiJapan
  7. 7.Osaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  8. 8.Tokyo Metropolitan Komagome HospitalTokyoJapan
  9. 9.Kanagawa Cancer CenterYokohamaJapan
  10. 10.Yamagata Prefectural Central HospitalYamagataJapan
  11. 11.Toyama Prefectural Central HospitalToyamaJapan
  12. 12.Cancer Institute HospitalTokyoJapan

Personalised recommendations